Lisocabtagene maraleucel may induce remission in relapsed chronic lymphocytic leukemia (CLL)
1. Complete response or remission was reported in 18% of patients who received a single liso-cel infusion. 2. Nearly 10% ...
Tag: chronic lymphocytic leukemia (CLL)
Pirtobrutinib is safe and efficacious in the treatment of relapsed or refractory B-cell malignancies (BRUIN Trial)
1. Bruton’s tyrosine kinase inhibitor pirtobrutinib showed efficacy in the treatment of relapsed or refractory B-cell malignancies such as chronic ...
#VisualAbstract: Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
1. Previously untreated chronic lymphocytic leukemia (CLL) patients experienced increased progression-free and overall survival when treated with ibrutinib-rituximab compared to ...
Survival increased in chronic lymphocytic leukemia patients treated with ibrutinib and rituximab
1. Previously untreated chronic lymphocytic leukemia (CLL) patients experienced increased progression-free and overall survival when treated with ibrutinib-rituximab compared to ...
#Visual Abstract: Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
1. In untreated chronic lymphocytic leukemia (CLL) patients with coexisting conditions, patients treated with venetoclax–obinutuzumab experienced greater progression-free survival compared ...
The CLL14 trial: longer progression-free survival for CLL patients with coexisting conditions treated with venetoclax
1. In untreated chronic lymphocytic leukemia (CLL) patients with coexisting conditions, patients treated with venetoclax–obinutuzumab experienced greater progression-free survival compared ...